解剖固定型覆膜支架治疗患者20年大样本长期临床结局及III型内漏预测因素
本研究在单中心前瞻性纳入、回顾性分析1999至2020年接受一体式覆膜支架腔内修复腹主动脉瘤的872例患者,按器械代次分层。III型内漏累积发生率为4.8%(42/872),AFXs组无III型内漏生存率显著更低(p<0.001),AFXs为独立危险因素(HR=3.1,p=0.003)。
要点
- III型内漏累积发生率为4.8%(42/872),AFXs组无III型内漏生存率显著更低(p<0.001)。
- AFXs为III型内漏独立危险因素(HR=3.1,p=0.003),使用单一组件降低风险(HR=0.3,p=0.005)。
- 主动脉瘤直径每增加10 mm,III型内漏风险增加2倍(HR=2.0,p<0.001)。
核心结论
- AFXs第一代覆膜支架与III型内漏风险增加3.1倍相关,作者认为对该器械植入患者需严格、细致的随访。
- 作者指出,植入这些器械并具有上述解剖特征的患者应在随访中接受密切监测。
研究设计与样本
- 单中心1999至2020年接受一体式覆膜支架腔内修复的患者前瞻性纳入、回顾性分析,按器械代次分层,共872例。
- 主要结局为一体式器械治疗患者中III型内漏的发生率,次要结局包括不同器械代次的III型内漏发生率、IIIa与IIIb型内漏的比较、危险因素分析及总生存与无III型内漏生存。
主要发现
- III型内漏累积发生率为4.8%(42/872)。
- 各代次发生率分别为Powerlink 2.4%(10/414)、AFXs 21.7%(15/69)、AFXd 4.6%(16/341)、AFX2 2.1%(1/48)。
- 按器械代次比较,AFXs组无III型内漏生存率显著更低(p<0.001)。
- 急诊EVAR(p=0.011)、大腹主动脉瘤(p<0.001)、成角及钙化瘤颈(p=0.002)、使用超过一个模块化组件或非专用延伸段(p<0.001)时III型内漏更多。
- AFXs为III型内漏独立危险因素(HR=3.1,p=0.003),使用单一组件降低风险(HR=0.3,p=0.005),主动脉瘤直径每增加10 mm风险增加2倍(HR=2.0,p<0.001)。
关键数值与推荐
- III型内漏累积发生率为4.8%(42/872)。
- AFXs为III型内漏独立危险因素(HR=3.1,p=0.003)。
- 使用单一组件降低III型内漏风险(HR=0.3,p=0.005)。
- 主动脉瘤直径每增加10 mm,III型内漏风险增加2倍(HR=2.0,p<0.001)。
临床怎么用
- 作者认为,植入AFXs的患者需严格、细致的随访。
- 作者指出,植入这些器械并具有成角及钙化瘤颈、大动脉瘤等特征的患者应在随访中接受密切监测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the incidence, outcomes, and predictors of type III endoleaks (TIIIELs) in patients treated with different generations of Endologix unibody devices for abdominal aortic aneurysm (AAA). METHODS: Patients treated with unibody endografts between 1999 and 2020 in a single unit were prospectively enrolled, retrospectively analyzed, and stratified according to device generation. The primary outcome was the incidence of TIIIEL in patients treated with unibody devices. Secondary outcomes included: (1) TIIIEL incidence among the different device generations; (2) comparison of type IIIa (TIIIaELs) and type IIIb endoleaks (TIIIbELs) incidence, treatment, and complications; (3) risk factor analysis for TIIIEL; (4) overall survival and survival free from TIIIEL. RESULTS: A total of 872 patients who underwent endovascular aortic repair (EVAR) were analyzed. The cumulative incidence of TIIIEL was 4.8% (42/872). The incidence among different generations was 2.4% (10/414), 21.7% (15/69), and 4.6% (16/341), and 2.1% (1/48) for Powerlink, AFXs, AFXd, and AFX2. Freedom from TIIIEL by device generation was significantly lower in the AFXs group (p<0.001). Type III endoleaks was higher in urgent EVAR (p=0.011), large AAA (p<0.001), angulated and calcified necks (p=0.002), and when more than one modular component or non-proprietary extension was used (p<0.001). AFXs was found as independent risk factor for TIIIEL (hazard ratio [HR]=3.1, p=0.003), while the use of a single component decreased the risk (HR=0.3, p=0.005). Finally, every 10-mm increase in AAA diameter resulted in a 2-fold increase in TIIIEL risk (HR=2.0, p<0.001). CONCLUSION: The first generation of AFX endograft was associated with an increase in TIIIEL risk by 3.1 times, claiming a strict and careful follow-up in patients implanted with this device.Clinical ImpactThe old-generation of unibody endograft AFXs was associated with an increase in TIIIEL risk by 3.1 times. Angulated and calcified neck, large aneurysms and the use of nonproprietary graft extension were found as independent risk factors for TIIIEL. Patients implanted with these devices and with these anatomical features should be intensively monitored during follow-up.
引用
- Leone N, Andreoli F, Baresi GF, et al. Long-term Clinical Outcomes and Predictors of Type-III Endoleak in a Large Cohort of Patients Treated With Anatomically Fixed Stent Grafts Over 20 Years. J Endovasc Ther. 2025. PMID: 39981823. doi:10.1177/15266028251317910
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。